How to test for MCAS · tryptase

How to Test for MCAS When Your Allergy Tests Keep Coming Back Negative

Testing for MCAS takes a paired tryptase draw: one value during or soon after a reaction and one at baseline. Under the strict consensus criteria, an episode counts when tryptase rises to at least baseline times 1.2, plus 2 ng/mL, and a standard allergy panel cannot show it because mast cell activation often involves no antibody.

A shrinking safe-food list and a clean allergy panel are not a contradiction. They usually mean the wrong test was run, at the wrong moment, for the wrong cell.

Flushing after meals, cramping within minutes, a list of safe foods that gets shorter every season, and an allergy panel that says nothing is wrong. When that pattern leads you to search how to test for MCAS, you have already found the first problem: the standard allergy workup looks for an antibody, and mast cell activation often involves no antibody at all.

In She’s Not Allergic to Her Food. She’s Fermenting It., a video drawn from The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, Dr. Padda follows a woman whose symptoms were twice labeled anxiety. What follows is the measurement side of her story: which tests exist, which ones mislead, and what Measura can and cannot add.

Why an allergy panel comes back clean

Mast cells are the sentinels of the first brain, the gut. They sit where the innate and adaptive arms of the immune system meet, and far more than the allergy antibody IgE can set them off. They also talk with sensory nerves in both directions. In irritable bowel syndrome, 34 of 44 patients, 77%, had more of their gut lining occupied by mast cells than controls did, and the cells lying closest to nerves were the ones that tracked pain.

Their chemicals are not harmless. Histamine, proteases, prostaglandins and cytokines drive both pain and a leakier gut wall at the same time. So cramping, loose stool and a permeable lining can be a single process that gets three separate labels and three separate prescriptions. An antibody test cannot see any of it, and the second brain, in the skull, gets blamed for signals coming from below.

Certain drugs can set off mast cells on their own by binding a receptor named MRGPRX2; no antibody or prior sensitization is involved. Morphine, vancomycin, rocuronium and atracurium are among the agents named. A negative allergy test does not clear a reaction to one of them.

How to test for MCAS: the tryptase rule and its rival

Tryptase is an enzyme mast cells release, and it anchors the strict consensus criteria. Normal serum tryptase runs 0 to 11.4 ng/mL. An episode counts when tryptase rises to at least the baseline times 1.2, plus 2 ng/mL, and all three diagnostic criteria must be met, not just one. From a baseline of 10, the bar sits at 14. The authors concede the formula favors specificity, which means it will miss some people.

The practical point is timing. The test is a pair: one value during or soon after a reaction and one at baseline. The paired draw is also the value most often missing from a chart.

A competing framework argues those criteria miss most patients and puts prevalence as high as 17% of the general population, while admitting in its own text that overdiagnosis is a risk. Both camps have a case. Anyone who gives you the diagnosis owes you which rulebook they used.

There is a genetic piece too. Carriers of hereditary alpha-tryptasemia made up 4% of healthy blood donors yet 29% of people with non-clonal mast cell activation, and carriers ran higher baseline tryptase. The strict committee suggests considering genotyping at a tryptase of 8 ng/mL or higher. That trait explains a number; in the cohort studied, it did not predict later anaphylaxis in patients whose illness began another way.

What histamine intolerance testing gets wrong

Many people land on a histamine intolerance label first. When referred patients were given histamine and placebo without knowing which, the diagnosis was excluded in 84.7% of them, and 62.7% reacted to the placebo. Only 4 of 59 had objective symptoms to histamine and not to placebo. The blood enzyme level often sold as a histamine intolerance test could not sort reactors from everyone else.

That does not mean the symptoms are imagined. It means dietary histamine is the wrong target for most people handed a low-histamine list. The histamine that matters appears to be made inside the gut: mice raised without gut microbes and given stool from IBS patients with high urinary histamine developed gut pain and mast cell activation, and when people with IBS ate less fermentable carbohydrate, their pain and the histamine in their urine both dropped.

The incentives explain why this gets missed. A food list costs nothing to hand out, antihistamines refill forever, and the hour needed to find out why the cells are firing is an hour the system does not reward.

Where Measura fits, and where it does not

Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service. It measures and sends results to your physician; it does not diagnose or treat. Tryptase, histamine, genotyping, biopsies and other mast cell tests are specialized tests done elsewhere, ordered by your physician or an allergist. Measura does not run them beyond general laboratory panels.

The bridge is the company mast cell problems keep. Orthostatic intolerance, hypermobility, gut overgrowth and polypharmacy travel together with mast cell activation, and in a chart review of low-dose naltrexone in dysautonomia, orthostatic intolerance was the reason for prescribing in 27.78% of patients. If standing makes your heart race or your head swim, that part is measurable:

• Autonomic nervous system testing looks at how blood pressure and heart rate regulation respond to position and stress.
• Cardiac autonomic reflex tests check heart rate responses to breathing and standing maneuvers.
• Heart rate variability gives a baseline reading of vagal tone.

Those results do not confirm or rule out MCAS. They document an autonomic picture your physician can weigh alongside tryptase and history. The overlap with joint hypermobility is covered in EDS and POTS, and the leaky-wall side in how to test for leaky gut.

What low-dose naltrexone is, and is not

Low-dose naltrexone often comes up with this diagnosis, and it is commonly mislabeled. Calling it a mast cell stabilizer gets the pharmacology backward. Naltrexone is inactive at MRGPRX2, the receptor opioids use to fire mast cells. The proposed route is indirect and upstream: a brief opioid blockade followed by a rebound rise in the body’s own endorphin, which may act on lymphocytes including regulatory T cells, plus antagonism of Toll-like receptor 4, the sensor for bacterial fragments, which thins the inflammatory signals that keep gut mast cells primed. The TLR4 link rests on cell and animal work, and the lymphocyte link is the least settled. In a survey of 553 patients, self-rated benefit averaged 5.6 out of 10, against 6.3 for antihistamines. Any medication decision belongs with your physician.

Questions to bring to your appointment

• Which criteria are being used for my diagnosis?
• Was tryptase drawn during a reaction and compared with a baseline value?
• Did the reactions start soon after antibiotics, a stomach bug or an operation?
• Is a drug reaction in my history one that fires mast cells directly?
• Should my dizziness or racing heart on standing be measured?

Once the source is addressed, the long-term upkeep is the subject of how to maintain weight loss and what to measure. Every study above, with its limits, is in the Chapter 31 Deep Dive.

Frequently asked questions

References

• Barbara, G., Stanghellini, V., De Giorgio, R., Cremon, C., Cottrell, G. S., Santini, D., Pasquinelli, G., Morselli-Labate, A. M., Grady, E. F., Bunnett, N. W., Collins, S. M., & Corinaldesi, R. (2004). Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology, 126(3), 693-702. https://doi.org/10.1053/j.gastro.2003.11.055
• Stassen, M., Hartmann, A.-K., Delgado, S. J., Dehmel, S., & Braun, A. (2019). Mast cells within cellular networks. The Journal of Allergy and Clinical Immunology, 144(4S), S46-S54. https://doi.org/10.1016/j.jaci.2019.01.031
• Hasler, W. L., Grabauskas, G., Singh, P., & Owyang, C. (2022). Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome. Neurogastroenterology and Motility, 34(7), e14339. https://doi.org/10.1111/nmo.14339
• Valent, P., Akin, C., Nedoszytko, B., Bonadonna, P., Hartmann, K., Niedoszytko, M., Brockow, K., Siebenhaar, F., Triggiani, M., Arock, M., Romantowski, J., Górska, A., Schwartz, L. B., & Metcalfe, D. D. (2020). Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. International Journal of Molecular Sciences, 21(23), 9030. https://doi.org/10.3390/ijms21239030
• Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., Cuni, J. R., Davey, W. P., Dempsey, T. T., Dorff, S. R., Dubravec, M. S., Guggenheim, A. G., Hindman, K. J., Hoffman, B., Kaufman, D. L., Kratzer, S. J., Lee, T. M., Marantz, M. S., Maxwell, A. J., … Molderings, G. J. (2020). Diagnosis of mast cell activation syndrome: a global “consensus-2”. Diagnosis (Berlin, Germany), 8(2), 137-152. https://doi.org/10.1515/dx-2020-0005
• González-de-Olano, D., Navarro-Navarro, P., Muñoz-González, J. I., Sánchez-Muñoz, L., Henriques, A., de-Andrés-Martín, A., Peralta-Arjonilla, D., Mayado, A., Jara-Acevedo, M., García-Montero, A. C., Orfao, A., & Álvarez-Twose, I. (2023). Clinical impact of the TPSAB1 genotype in mast cell diseases: a REMA study in a cohort of 959 individuals. Allergy, 79(3), 711-723. https://doi.org/10.1111/all.15911
• Bent, R. K., Kugler, C., Faihs, V., Darsow, U., Biedermann, T., & Brockow, K. (2023). Placebo-controlled histamine challenge disproves suspicion of histamine intolerance. The Journal of Allergy and Clinical Immunology: In Practice, 11(12), 3724-3731.e11. https://doi.org/10.1016/j.jaip.2023.08.030
• De Palma, G., Shimbori, C., Reed, D. E., Yu, Y., Rabbia, V., Lu, J., Jimenez-Vargas, N., Sessenwein, J., Lopez-Lopez, C., Pigrau, M., Jaramillo-Polanco, J., Zhang, Y., Baerg, L., Manzar, A., Pujo, J., Bai, X., Pinto-Sanchez, M. I., Caminero, A., Madsen, K., … Bercik, P. (2022). Histamine production by the gut microbiota induces visceral hyperalgesia through histamine 4 receptor signaling in mice. Science Translational Medicine, 14(655), eabj1895. https://doi.org/10.1126/scitranslmed.abj1895
• Lansu, K., Karpiak, J., Liu, J., Huang, X.-P., McCorvy, J. D., Kroeze, W. K., Che, T., Nagase, H., Carroll, F. I., Jin, J., Shoichet, B. K., & Roth, B. L. (2017). In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nature Chemical Biology, 13(5), 529-536. https://doi.org/10.1038/nchembio.2334
• Zapata, N., Georgiadi, E., Cantrell, C., Rilinger, R. G., Levine, M. A., & Wilson, R. (2025). Low-dose naltrexone for managing pain and autonomic symptoms in patients with dysautonomia. Cureus, 17(6), e86538. https://doi.org/10.7759/cureus.86538

Related reading

• How to Maintain Weight Loss When the Scale Stops Telling the Truth
• Does Nicotine Raise Heart Rate? What Measurement Can Show
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.